INTRODUCTION

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia. Cluster headache is less prevalent than migraine and characterized by attacks of severe, unilateral pain with ipsilateral autonomic symptoms, which occur every other day to multiple times daily during a cluster period (International Headache Society [IHS] 2018, Starling et al 2015).

- The pathophysiology of migraines is assumed to involve the activation of trigeminal sensory nerves. CGRP is involved in pathophysiology through nociceptive mechanisms in the trigeminovascular system. CGRP is a vasodilator and is found at higher concentrations during a migraine attack. Vasodilation of dural blood vessels may occur with extravasation of dural plasma, resulting in inflammation (Goadsby et al 2017, Starling et al 2015, Silberstein et al 2012).

- The International Classification of Headache Disorders (ICHD) includes both cluster headache and migraine as part of a group of primary headache disorders (IHS 2018):
  - Chronic migraine is defined as ≥ 15 headache days per month for > 3 months with the features of migraine headache for at least 8 migraine days per month (MMD). The most common cause of symptoms suggestive of chronic migraine is medication overuse. According to the ICHD, around 50% of patients apparently with chronic migraine revert to an episodic migraine type after drug withdrawal; such patients are in a sense wrongly diagnosed with chronic migraine. In most clinical trials, migraine that is not chronic (ie, < 15 headache days per month) is considered to be episodic migraine, although the condition is not clearly defined in the ICHD.
  - Cluster headache is defined as ≥ 5 attacks lasting 15 to 180 minutes every other day to 8 times a day with severe unilateral orbital, supraorbital, and/or temporal pain. Episodic cluster headache attacks occur for a period of 7 days to 1 year and are separated by pain-free periods lasting at least 3 months. Common symptoms include nasal congestion, rhinorrhea, conjunctival injection and/or lacrimation, eyelid edema, sweating (forehead or face), miosis, ptosis, and/or a sense of restlessness or agitation.

- Cluster headache is more likely to occur in men, whereas migraines are more likely to occur in women. Migraines have a global prevalence of 15 to 18% and are a leading cause of disability worldwide. Chronic migraine is estimated to occur in 2 to 8% of patients with migraine, whereas episodic migraine occurs in more than 90% of patients. Cluster headache is rare compared to other primary headache disorders. It is estimated to have a prevalence of 0.1% within the general population (Global Burden of Disease Study [GBD] 2016, Hoffman et al 2018, Lipton et al 2016, Ljubisavljevic et al 2019, Manack et al 2011).

- Treatments for migraines and cluster headache are divided into acute and preventive therapies. Evidence and reputable guidelines clearly delineate appropriate therapies for episodic migraine treatment and prophylaxis; options stretch across a wide variety of therapeutic classes and are usually oral therapies. For the prevention of migraines, treatment options include oral prophylactic therapies, injectable prophylactic therapies, and neuromodulator devices. Oral prophylactic migraine therapies have modest efficacy, and certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy. For the treatment of cluster headache, subcutaneous sumatriptan, zolmitriptan nasal spray, and oxygen have the most positive evidence for acute therapy, and suboccipital steroid injections are most effective for prevention (American Migraine Foundation [AMF] 2017, Robbins et al 2018, Silberstein et al 2012, Simpson et al 2016).

- The CGRP pathway is important in pain modulation. Erenumab-aooe is a fully human monoclonal antibody, which potently binds to the CGRP receptor in a competitive and reversible manner with greater selectivity than to other human calcitonin family receptors. Fremanezumab-vfrm and galcanezumab-gnlm are 2 humanized monoclonal antibodies that target and potently bind the CGRP ligand, in most cases both the α and β isoforms (Dodick et al 2018[b], Edvinsson 2017, Goadsby et al 2017, Silberstein et al 2017, Sun et al 2016, Tepper et al 2017).
  - All 3 of the available CGRP inhibitors are indicated for the preventive treatment of migraine in adults. Additionally, galcanezumab-gnlm is indicated for the treatment of episodic cluster headache in adults.
  - In April 2019, Teva announced that fremanezumab-vfrm would not pursue development of episodic cluster headache due to results from the ENFORCE trial (Teva Pharmaceuticals press release 2019). Erenumab-aooe is not currently in early phase studies for the indication of cluster headache (Clinicaltrials.gov 2019).
Medispan class: Migraine products – monoclonal antibodies; Calcitonin gene–related peptide (CGRP) receptor antagonists

Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimovig (erenumab–aooe)</td>
<td>−</td>
</tr>
<tr>
<td>Ajovy (fremanezumab-vfrm)</td>
<td>−</td>
</tr>
<tr>
<td>Emgality (galcanezumab-gnlm)</td>
<td>−</td>
</tr>
</tbody>
</table>

(Drugs@FDA 2019, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2019)

INDICATIONS

Table 2. Food and Drug Administration Approved Indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Aimovig (erenumab–aooe)</th>
<th>Ajovy (fremanezumab-vfrm)</th>
<th>Emgality (galcanezumab-gnlm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventive treatment of migraine in adults</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Treatment of episodic cluster headache in adults</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>


Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

CLINICAL EFFICACY SUMMARY

Erenumab-aooe has been studied in approximately 2500 patients across 4 trials in patients with episodic or chronic migraine subtypes and 1 open-label extension (OLE) trial with data from interim analyses in published and unpublished formats.

Fremanezumab-vfrm has been studied in approximately 2005 patients across 3 trials in patients with episodic or chronic migraine subtypes, with data in published formats. In fremanezumab-vfrm trials, the definition of a headache or migraine day for the primary endpoint required a consecutive 2 hour (episodic) or 4 hour (chronic) duration of pain, compared to other CGRP inhibitor trials which required a duration of ≥ 30 minutes.

Galcanezumab-gnlm has been studied in approximately 2886 patients across 3 trials in patients with episodic or chronic migraine subtypes and 1 long-term safety trial with unpublished data to 1 year. The efficacy and safety of galcanezumab-gnlm was evaluated in one 8-week study with 106 adults with episodic cluster headache (maximum of 8 attacks/day).

The definition of the primary and secondary endpoints differed in the prevention of episodic and chronic migraine trials. Additional differences included, but were not limited to, co-morbid conditions, concomitant medications, a requirement of stable doses of migraine prevention medication (if co-administered) for certain durations, the definition of headache, migraine headache, and migraine day. Some CGRP inhibitor trials allowed patients to receive concomitant preventive migraine medication during treatment. Also, some chronic migraine trials allowed for the inclusion of patients with medication overuse headache.

Prevention of episodic migraine

Erenumab-aooe

The STRIVE trial was a 6-month, double-blind (DB), placebo-controlled (PC), multi-center (MC), Phase 3 trial in which 955 patients with episodic migraine were randomized to placebo (n = 319), erenumab-aooe 70 mg (n = 317), or erenumab-aooe 140 mg (n = 319) once monthly. The primary endpoint was the change in mean MMD from baseline to months 4 to 6, which favored treatment with erenumab–aooe 70 mg (mean change vs placebo, −1.4; 95% confidence interval [CI], −1.9 to −0.9; p < 0.001) and erenumab–aooe 140 mg (mean change vs placebo, −1.9; 95% CI, −2.3 to −1.4; p < 0.001). Erenumab–aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 70 mg vs placebo, 16.7%; odds ratio [OR], 2.13; difference for 140 mg vs placebo, 23.4%; OR, 2.81). Erenumab–aooe was also associated with a significant decrease in the mean monthly acute migraine–specific
medication treatment days (difference for 70 mg vs placebo, −0.9; difference for 140 mg vs placebo, −1.4) (Goadsby et al 2017).

The ARISE trial was a 12-week, DB, PC, MC, Phase 3 trial in which 577 patients with episodic migraine were randomized to placebo (n = 291) or erenumab-aooe 70 mg (n = 286) once monthly. The primary endpoint was the change in MMD from baseline to weeks 9 to 12, which favored treatment with erenumab−aooe 70 mg (mean change vs placebo, −1.0; 95% CI, −1.6 to −0.5; p < 0.001). Compared to placebo, erenumab−aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference, 10.2%; OR, 1.59). Erenumab−aooe was also associated with a significant decrease in the mean monthly acute migraine−specific medication treatment days (difference, −0.6) (Dodick et al 2018[a]).

The LIBERTY trial was a 12-week, DB, PC, MC, Phase 3b trial in which 246 patients with episodic migraine who failed 2 to 4 prior preventive migraine treatments were randomized to placebo (n = 125) or erenumab-aooe 140 mg (n = 121) once monthly. The primary endpoint was the proportion of patients with ≥ 50% reduction in MMD from baseline to the last 4 weeks of DB treatment (weeks 9 to 12), which erenumab−aooe significantly increased over placebo (difference, 16.6%; OR, 2.73; 95% CI, 1.43 to 5.19; p = 0.002). Compared to placebo, a total of 5.9% more patients treated with erenumab−aooe 140 mg reported a 100% reduction in MMD, or migraine cessation. Erenumab 140 mg/month compared with placebo significantly reduced the MMD (difference, −1.61; 95% CI, −2.70 to −0.52; p = 0.004). Erenumab−aooe was also associated with a significant decrease in the mean monthly acute migraine−specific medication treatment days (difference, −1.73) (Reuter et al 2018).

**Fremanezumab-vfrm**

The HALO-EM trial was a 12-week, DB, PC, MC, Phase 3 trial in which 875 patients with episodic migraine were randomized to placebo (n = 291), fremanezumab-vfrm 225 mg once monthly (n = 290), or fremanezumab-vfrm 675 mg once quarterly (n = 291). The primary endpoint was the proportion of patients with ≥ 50% reduction in MMD from baseline to the last 4 weeks of DB treatment (weeks 9 to 12), which fremanezumab-vfrm significantly increased over placebo (difference, 16.6%; OR, 2.73; 95% CI, 1.43 to 5.19; p = 0.002). Of note, HALO-EM was powered to detect a 1.6-day difference in the MMD between the fremanezumab-vfrm and placebo groups, but effect sizes resulted in a 1.5-day reduction for the fremanezumab-vfrm monthly dosing group and a 1.3-day reduction for the fremanezumab-vfrm quarterly dosing group. Although the threshold was not reached, a minimal clinically important difference has not been established for this particular outcome. Compared to placebo, greater MMD reductions were also observed in patients who were prescribed fremanezumab-vfrm 225 mg (mean change vs placebo, −1.3) and 675 mg (mean change vs placebo, −1.1) as monotherapy. Fremanezumab-vfrm significantly increased the proportion of patients achieving ≥ 50% reduction in MMD (difference for 225 mg vs placebo, 19.8%; OR, 2.36; difference for 675 mg vs placebo, 16.5%; OR, 2.06). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine−specific medication treatment days (difference for 225 mg vs placebo, −1.4; difference for 675 mg vs placebo, −1.3) (Dodick et al 2018[b]).

**Galcanezumab-gnlm**

The EVOLVE-1 and EVOLVE-2 trials were 6-month, DB, PC, MC, Phase 3 trials in 858 and 915 patients with episodic migraine, respectively. Patients were randomized to placebo (EVOLVE-1, n = 433; EVOLVE-2, n = 461), galcanezumab-gnlm 120 mg once monthly (EVOLVE-1, n = 213; EVOLVE-2, n = 231), or galcanezumab-gnlm 240 mg once monthly (EVOLVE-1, n = 212; EVOLVE-2, n = 223). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The EVOLVE-1 trial included a North American population and the EVOLVE-2 trial included a global population. The primary endpoint was the change in mean monthly migraine headache days (MMHD) (Stauffer et al 2018, Skljarevski et al 2018).

- In EVOLVE-1, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −1.9; 95% CI, −2.5 to −1.4; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.8; 95% CI, −2.3 to −1.2; p < 0.001). Galcanezumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMHD (difference for 120 mg vs placebo, 23.7%; OR, 2.64; difference for 240 mg vs placebo, 22.3%; OR, 2.50). Compared to placebo, a total of 9.4% more patients treated with galcanezumab-gnlm 120 mg and 9.4% more treated with galcanezumab-gnlm 240 mg reported a 100% reduction in MMHD, or migraine cessation. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine−specific medication treatment days (difference for 120 mg vs placebo, −1.8; difference for 240 mg vs placebo, −1.6) (Stauffer et al 2018).
- In EVOLVE-2, the primary endpoint outcome favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −2.0; 95% CI, −2.6 to −1.5; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.9;
Galcanezumab-gnlm was evaluated in a 12-week, DB, PC, MC, Phase 3 trial, REGAIN, in which 1113 patients with chronic migraine were randomized to placebo (n = 558), galcanezumab-gnlm 120 mg once monthly (n = 278), or galcanezumab-gnlm 240 mg once monthly (n = 277). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The primary endpoint was the change in mean monthly headache days (MMHD), which favored treatment with galcanezumab-gnlm 240 mg (mean change vs placebo, −1.9; 95% CI, −2.7 to −1.1; p < 0.0001). In an analysis of persistence for patients with chronic migraine, a total of 29% of galcanezumab-gnlm-treated patients (120 mg and 240 mg, respectively) had a ≥ 30% response for ≥ 3 months, which was greater than placebo (16.8% vs 12.2%, p < 0.001). Fewer patients (3.6%) maintained ≥ 75% response for all 6 months vs 2% of placebo-treated patients. Few galcanezumab-gnlm-treated patients maintained 100% response for all 6 months (< 1.5%) (Förderreuther et al 2018).

Prevention of chronic migraine

Erenumab-aooe
- Erenumab-aooe was studied in a 12-week, DB, PC, MC, Phase 2 trial in which 667 patients with chronic migraine were randomized to placebo (n = 286), erenumab-aooe 70 mg (n = 191), or erenumab-aooe 140 mg (n = 190) once monthly. The primary endpoint was the change in mean headache days (MHD), which favored treatment with erenumab-aooe 140 mg (mean change vs placebo, −2.5; 95% CI, −3.5 to −1.4; p < 0.0001). Erenumab-aooe significantly increased the proportion of patients achieving ≥ 50% reduction in MHD (difference for 70 mg vs placebo, 17%; OR, 2.2; difference for 140 mg vs placebo, 18%; OR, 2.3). Both erenumab-aooe 70 mg (difference, −1.9) and erenumab-aooe 140 mg (difference, −2.6) significantly reduced the mean acute migraine-specific medication days; however, the higher 140 mg dose had a greater reduction numerically over placebo and reductions may be dose-dependent (Tepper et al 2017).

Fremanezumab-vfrm
- Fremanezumab-vfrm was studied in a 12-week, DB, PC, MC, Phase 3 trial, HALO-CM, in which 1130 patients with chronic migraine were randomized to placebo (n = 375), fremanezumab-vfrm 225 mg once monthly (n = 379), or fremanezumab-vfrm 675 mg once quarterly (n = 376). Patients in the fremanezumab-vfrm 225 mg group received a loading dose of 675 mg at the first injection only. The primary endpoint was the change in mean headache days (MHD), which favored treatment with fremanezumab-vfrm 225 mg (mean change vs placebo, −2.1; standard error [SE], ± 0.3; p < 0.001) and fremanezumab-vfrm 675 mg (mean change vs placebo, −1.8; SE, ± 0.3; p < 0.001). Fremanezumab-vfrm significantly increased the proportion of patients achieving ≥ 50% reduction in MHD (difference for 225 mg vs placebo, 22.7%; OR, 2.73; difference for 675 mg vs placebo, 19.5%; OR, 3.13). Additionally, fremanezumab-vfrm was associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 225 mg vs placebo, −2.3; difference for 675 mg vs placebo, −1.8) (Silberstein et al 2017).

Galcanezumab-gnlm
- Galcanezumab-gnlm was evaluated in a 12-week, DB, PC, MC, Phase 3 trial, REGAIN, in which 1113 patients with chronic migraine were randomized to placebo (n = 286), galcanezumab-gnlm 120 mg once monthly (n = 278), or galcanezumab-gnlm 240 mg once monthly (n = 277). Patients in the galcanezumab-gnlm 120 mg group received a loading dose of 240 mg at the first injection only. The primary endpoint was the change in MMHD, which favored treatment with galcanezumab-gnlm 120 mg (mean change vs placebo, −2.1; 95% CI, −2.9 to −1.3; p < 0.001) and galcanezumab-gnlm 240 mg (mean change vs placebo, −1.9; 95% CI, −2.7 to −1.1; p < 0.001). Galcanezumab-gnlm significantly increased the proportion of patients achieving ≥ 50% reduction in MMHD (difference for 120 mg vs placebo, 12.2%; OR, 2.10; difference for 240 mg vs placebo, 12.1%; OR, 2.10). Compared to placebo, a total of 0.2% more patients treated with galcanezumab-gnlm 120 mg and 0.8% more treated with galcanezumab-gnlm 240 mg reported migraine cessation; this was not statistically different for either dose group. Galcanezumab-gnlm was also associated with a significant decrease in the mean monthly acute migraine-specific medication treatment days (difference for 120 mg vs placebo, −2.5; difference for 240 mg vs placebo, −2.1) (Detke et al 2018).

In an analysis of persistence for patients with chronic migraine, 29% of galcanezumab-gnlm-treated patients maintained ≥ 30% response all 3 months compared to 16% of placebo-treated patients. A total of 16.8 and 14.6% of galcanezumab-gnlm-treated patients (120 mg and 240 mg, respectively) had a ≥ 50% response for ≥ 3 months, which was greater than placebo (6.3%; p < 0.001). Few patients maintained ≥ 75% response (< 3%) (Förderreuther et al 2018).
**Treatment of episodic cluster headache**

**Galcanezumab-gnlm**

- Galcanezumab-gnlm was evaluated in an 8-week, unpublished, DB trial, in which 106 patients with episodic cluster headache were randomized to placebo (n = 57) or galcanezumab-gnlm 300 mg once monthly (n = 49). A total of 90 (85%) patients completed the DB phase. Patients were allowed to use certain specified acute/abortive cluster headache treatments, including triptans, oxygen, acetaminophen, and NSAIDs during the study. At baseline, patients had a mean of 17.5 headache attacks/week, maximum of 8 attacks/day, minimum of 1 attack every other day, and at least 4 attacks during the prospective 7-day baseline period. For the primary endpoint, galcanezumab-gnlm significantly decreased the mean change from baseline in weekly cluster headache attack frequency during weeks 1 to 3 vs placebo (-8.7 vs -5.2 attacks; p = 0.036). Galcanezumab-gnlm was also associated with a significantly greater proportion of responders (≥ 50% reduction in weekly cluster headache attack frequency) at week 3 (71.4 vs 52.6%; p = 0.046) ([Clinicaltrials.gov](https://Clinicaltrials.gov) [NCT02397473] 2019, *Emgality prescribing information* 2019).

**Open-label extensions (OLE) and long-term safety studies**

- One published OLE with data to 1 year and 1 unpublished abstract with data to ≥ 3 years evaluated erenumab-aooe 70 mg (protocol amended to include 140 mg doses) in patients with episodic migraine. Of 472 patients in the parent study, a total of 308 patients completed 1 year of open-label (OL) treatment. For the ≥ 3 year assessment, of the 383 patients enrolled in the OLE, 250 continued into the 140 mg once monthly dosing. At the time of interim analysis, 236 patients remained in the OLE ([Amgen [data on file] 2018, Ashina et al 2017, Ashina et al 2018](https://Amgen[data on file] 2018, Ashina et al 2017, Ashina et al 2018)).
  - There may be greater improvements with sustained therapy based on a 1-year OLE interim analysis of episodic migraine patients treated with erenumab-aooe 70 mg once monthly. Patients had a mean value of 8.8 MMDs at parent study baseline. After 3 months of treatment in the parent study, the number of MMDs was reduced to 6.3 days (mean change of 2.5 days). After a total of 16 months of treatment, the number of MMDs was reduced to 3.7 days (mean change of 5.1 days). After 64 weeks, a total of 65% (n = 184) of episodic migraine patients achieved a ≥ 50% reduction in MMDs and 26% (n = 73) had achieved a migraine-free status. The most frequently reported adverse events (≥ 4.0 per 100 patient-years) were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, influenza, and back pain.

- One unpublished OLE evaluated erenumab-aooe 70 mg (protocol amended to include 140 mg doses) with data to 1 year in patients with chronic migraine. A total of 609 patients with chronic migraine enrolled in the OLE. A total of 199 increased their dose from 70 mg to 140 mg by week 28 ([Amgen [data on file] 2018, Tepper et al 2018](https://Amgen[data on file] 2018, Tepper et al 2018)).
  - Patients with chronic migraine had a mean value of 18.8 MMDs at parent study baseline. After a total of 1 year of treatment, the number of MMDs was reduced to 8.5 in the erenumab-aooe 70 mg group and 10.5 in the erenumab-aooe 140 mg group. After 1 year of erenumab-aooe 70 mg and 140 mg monthly dosing, a total of 53% and 67% of chronic migraine patients achieved a ≥ 50% reduction in MMDs and 6% and 13% had achieved a migraine-free status, respectively. The most frequently reported adverse events (≥ 2.0 per 100 patient-years) were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, and arthralgia.

- Another unpublished safety study, the CGAJ study, evaluated galcanezumab-gnlm 120 mg (plus 240 mg loading dose) and 240 mg monthly dosing to 1 year in patients with episodic or chronic migraine. At baseline, 80.7% of patients in the galcanezumab-gnlm 120 mg arm and 77.0% in the galcanezumab-gnlm 240 mg arm had episodic migraine. A total of 270 patients who had a history of ≥ 4 MHMDs and ≥ 1 headache-free day/month for the past 3 months continued galcanezumab-gnlm treatment ([Eli Lilly and Company [data on file] 2018, Emgality [dossier] 2018, Stauffer et al 2017](https://Eli Lilly and Company[data on file] 2018, Emgality[dossier] 2018, Stauffer et al 2017)).
  - At baseline, patients had a mean value of 9.7 to 11.4 (standard deviation [SD], 6.0 to 6.6) MHMDs. After a total of 1 year of treatment, the number of MHMDs was reduced to 5.6 days in the galcanezumab-gnlm 120 mg group and 6.5 days in the galcanezumab-gnlm 240 mg group. After ≥ 12 consecutive months of treatment, 24.2% of patients treated with galcanezumab-gnlm 120 mg and 34.8% of patients treated with galcanezumab-gnlm 240 mg maintained response. The most frequently reported adverse events (incidence ≥ 15.0%) were injection site pain, nasopharyngitis, and upper respiratory tract infections. One patient discontinued due to suicidal ideation in the galcanezumab-gnlm 120 mg group. There were no overall concerns regarding safety or tolerability.

- Caution should be exercised in applying results from extension trials. The OL design may contribute to biased reports. Extension trials may have biased outcomes because those experiencing benefit are included in extension trials; results are useful for reporting trends in treatment. Additionally, there is no comparator to account for placebo effects.
CLINICAL GUIDELINES

Prevention of migraine
- According to the American Academy of Neurology and American Headache Society (AAN/AHS) evidence-based guideline update on the pharmacologic treatment for episodic migraine prevention in adults (Silberstein et al 2012), the following medications are effective preventive treatment options (see Appendix A for a definition of classifications):
  - Level A (established efficacy and > 2 Class I trials):
    - Antiepileptic drugs: divalproex sodium, sodium valproate, and topiramate
    - Beta blockers: metoprolol, propranolol, and timolol
    - Triptans (for menstrual related migraine [MRM]): for short-term prophylaxis, frovatriptan
  - Level B (probably effective and 1 Class I or 2 Class II trials):
    - Antidepressants: amitriptyline and venlafaxine
    - Beta blockers: atenolol and nadolol
    - Triptans (for MRM): for short-term prophylaxis, naratriptan and zolmitriptan
  - Level C (possibly effective and 1 Class II trial):
    - Angiotensin–converting enzyme (ACE) inhibitors: lisinopril
    - Angiotensin II receptor blockers (ARBs): candesartan
    - Alpha agonists: clonidine and guanfacine
    - Antiepileptic drugs: carbamazepine
    - Beta blockers: nebivolol and pindolol
    - Antihistamines: cyproheptadine
- The AAN recommends onabotulinumtoxin A as an effective treatment option that should be offered for chronic migraine. However, onabotulinumtoxin A is considered ineffective for the treatment of episodic migraines and should not be offered. There is insufficient evidence to compare the effectiveness of botulinum neurotoxin A with that of oral prophylactic topiramate (Simpson et al 2016).

Cluster headache
- According to the AHS evidence-based guidelines for the treatment of cluster headache (Robbins et al 2016), there are a number of effective treatment options (AAN classifications were used for grading; see Appendix A for definitions).
  - For acute therapy of cluster headache, the following therapy options have positive evidence:
    - Level A (established efficacy and ≥ 2 Class I trials):
      - Certain triptans: sumatriptan subcutaneous and zolmitriptan nasal spray
      - Oxygen
    - Level B (probably effective and 1 Class I or 2 Class II trials):
      - Certain triptans: sumatriptan nasal spray and zolmitriptan oral
      - Sphenopalatine ganglion stimulation
    - Level C (possibly effective and 1 Class II trial):
      - Cocaine/lidocaine nasal spray
      - Octreotide subcutaneous
  - For preventive therapy of cluster headache, the following therapy options have positive evidence:
    - Level A (established efficacy and ≥ 2 Class I trials):
      - Suboccipital steroid injection
    - Level B (probably effective and 1 Class I or 2 Class II trials):
      - Civamide nasal spray (not marketed in the US)
    - Level C (possibly effective and 1 Class II trial):
      - Lithium
      - Verapamil
      - Warfarin
      - Melatonin
SAFETY SUMMARY

- **All CGRP inhibitors** are contraindicated in patients with serious hypersensitivity to the active ingredient or any of the excipients. Mild to moderate hypersensitivity reactions (eg, rash, pruritus, urticaria) were reported in trials. **Reactions to erenumab-aooe have also included anaphylaxis and angioedema. In cases of serious or severe reactions, treatment should be discontinued.**

- **For the prevention of migraine**, the CGRP inhibitors generally have a similar incidence of adverse events as placebo. Very few severe adverse events and treatment discontinuations due to adverse events were reported. The most common adverse reactions observed in CGRP inhibitor studies included injection site reactions (all agents) and constipation (erenumab-aooe only). For the treatment of episodic cluster headache, galcanezumab-gnlm was evaluated for 2 months in trials and the safety profile was similar to those adverse events observed in migraine prevention trials. Two patients discontinued DB treatment due to adverse events.

- Caution should be exercised as long-term safety is unknown. CGRP is a vasodilator and is found at higher concentrations during a migraine attack. In the 1-year interim analysis of an OLE study with erenumab-aooe, 2 patients had severe adverse events (an arteriosclerosis event and a myocardial ischemia event), of which 1 was fatal and 1 was confounded by sumatriptan administration. No additional concerns were raised within the OLE at ≥ 3 years, including any cardiovascular events. In a long-term safety study of patients treated with galcanezumab-gnlm for 1 year, 1 patient discontinued due to suicidal ideation in the galcanezumab-gnlm 120 mg group. The long-term implications of prolonged CGRP inhibition are not fully established and safety has not been fully characterized (Amgen [data on file] 2018, Ashina et al 2017, Ashina et al 2018, Eli Lilly and Company [data on file] 2018, Stauffer et al 2017, Tepper et al 2018).

- There are no adequate data on the risks associated in patients who are pregnant or nursing, or in adolescent or pediatric populations.

---

**DOSING AND ADMINISTRATION**

Table 3. Dosing and Administration

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimovig (erenumab-aooe)</td>
<td>Auto-injector (70 mg/mL or 140 mg/mL)</td>
<td>SC</td>
<td>Once monthly (70 or 140 mg)</td>
<td>May be self-administered by patients in the abdomen, thigh, or back of upper arm. Latex-sensitive patients may have an allergic reaction to the needle shield within the white cap and the gray needle cap of the syringe. Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, erenumab-aooe has a limited stability of 7 days.</td>
</tr>
<tr>
<td>Ajovy (fremanezumab-vfrm)</td>
<td>Prefilled syringe (225 mg/1.5 mL)</td>
<td>SC</td>
<td>Once monthly (225 mg) or once every 3 months (675 mg)</td>
<td>May be self-administered by patients in the abdomen, thigh, or back of upper arm. The prefilled syringe cap is not made with natural rubber latex. Must be refrigerated and protected from light until time of use. Once removed from the refrigerator,</td>
</tr>
<tr>
<td>Drug</td>
<td>Available Formulations</td>
<td>Route</td>
<td>Usual Recommended Frequency</td>
<td>Comments</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------</td>
<td>-------</td>
<td>-------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Emgality</td>
<td>Auto-injector (120 mg/mL) Prefilled syringe (100 mg/mL or 120 mg/mL)</td>
<td>SC</td>
<td>Prevention of migraine: 2 consecutive injections (120 mg each) as a loading dose, then once monthly</td>
<td>fremanezumab-vfrm has a limited stability of 24 hours. May be self-administered by patients in the abdomen, thigh, back of upper arm or buttocks. The cap is not made with natural rubber latex. Must be refrigerated and protected from light until time of use. Once removed from the refrigerator, galcanezumab-gnlm has a limited stability of 7 days.</td>
</tr>
</tbody>
</table>

See the current prescribing information for full details

**Note:** With all of the CGRP inhibitors, there are no data in pregnant women or breastfed infants. A benefit/risk assessment should be taken into consideration prior to administering.

**CONCLUSION**

- Migraine is a common, recurrent, incapacitating disorder characterized by moderate to severe headaches and disabling features, including nausea, vomiting, neurologic symptoms, photophobia, and phonophobia. Migraines have a spectrum of frequency and severity that can significantly affect the quality of life of patients. Cluster headache is less prevalent than migraine and characterized by attacks of severe, unilateral pain with ipsilateral autonomic symptoms, which occur every other day to multiple times daily during a cluster period. Cluster headache is more likely to occur in men, whereas migraines are more likely to occur in women.

- All CGRP inhibitors are indicated for the prevention of migraine. Galcanezumab-gnlm has an additional indication for the treatment of episodic cluster headache.

- Guidelines have not been updated to include the CGRP inhibitors.
  - Current evidence-based prophylactic migraine treatment options and guidance are limited for chronic migraine, and oral prophylactic medications prescribed for episodic migraine are often used for the preventive treatment of chronic migraine. Prophylactic migraine treatment options include oral agents (mainly anti-seizure agents, antidepressants, and beta blockers), injectable agents (onabotulinumtoxin A for chronic subtypes only), or neuromodulation devices for migraine or headache attacks. Certain oral therapies may not be appropriate for individual patients due to intolerability or eventual lack of efficacy. There is no optimal prophylactic migraine therapy and head-to-head trials are lacking.
  - For the treatment of cluster headache, subcutaneous sumatriptan, zolmitriptan nasal spray, and oxygen have the most positive evidence for acute therapy according to the AHS guidelines. To date, only subcutaneous sumatriptan is FDA-approved for the acute treatment of cluster headache. Additionally, sumatriptan nasal spray, zolmitriptan oral formulations, and sphenopalatine ganglion stimulation are probably effective for acute treatment per guidelines. For prevention of cluster headaches, suboccipital steroid injections are most effective according to the guidelines; however, there is no preventive medication currently FDA-approved for cluster headache.
  - The CGRP inhibitors (erenumab-aooe, fremanezumab-vfrm, and galcanezumab-gnlm) are novel agents developed as alternatives for patients who do not tolerate, or do not have an adequate response to, currently marketed preventive migraine therapies. Galcanezumab-gnlm has an additional indication for the treatment of episodic cluster headaches.
  - Like other preventive medications for migraine, the CGRP inhibitors are not likely to render patients migraine-free. Based on 3 to 6 month data, primary endpoint reductions are similar to many oral prophylactic therapies; however, comparisons are limited as endpoints have been inconsistently defined. There are limited analyses and trials examining efficacy in patients who failed ≥ 2 prior preventive therapies; however, available data suggest that these patients may achieve greater reductions in migraine/headache frequency. Further research is warranted.
  - For the treatment of cluster headaches, galcanezumab-gnlm demonstrated efficacy compared to placebo in an unpublished 8-week trial, which allowed for acute/abortive treatments during therapy. Galcanezumab-gnlm significantly decreased the mean change from baseline in weekly cluster headache attack frequency by 3.5 during...
weeks 1 to 3 vs placebo. Additionally, 18.8% more patients were classified as responders (≥ 50% reduction in weekly cluster headache attack frequency) with galcanezumab-gnlm at week 3 vs placebo (p = 0.046).

- There are no head-to-head studies with the CGRP inhibitors and no prophylactic migraine agent is clearly superior to others.
  - Compared to placebo, the CGRP inhibitors consistently demonstrated modest but statistically significant reductions in primary endpoint measures (eg, MMD, MMH, or MMHD) ranging from 1.0 to 2.5 days after 3 to 6 months of treatment. Overall, the odds for a 50% reduction in MM(H)D were approximately 1.6 to 3.1 times higher with the CGRP inhibitors than placebo with numbers-needed to treat (NNTs) ranging from 3 to 10.
  - Lack of information during pregnancy and breastfeeding is a consideration as many migraine patients are women of childbearing potential. The unknown risks of monoclonal antibodies and the effects on certain conditions are not fully characterized. Important co-morbid populations were excluded from trials (eg, anxiety, depression, hypertension, and fibromyalgia), which also limits the generalizability to broader groups. There are no data in adolescents and children. Based on current data, the safety profiles of the CGRP inhibitors are generally mild with the most common adverse effects observed being injection site reactions.
  - Overall, the CGRP inhibitors represent another therapy option in the prevention of episodic or chronic migraine. Fremanezumab-vfrm is the only agent in the class that may be administered quarterly, which may fulfill a niche in patients who are non-adherent with treatment. Galcanezumab-gnlm is the only CGRP inhibitor indicated for the treatment of episodic cluster headaches and frequency of administration (and dose) vary by indication. Further long-term study is warranted.

### APPENDIX

- **Appendix A. AAN levels of evidence classification** *(Gronseth et al 2011)*

<table>
<thead>
<tr>
<th>Rating of recommendation</th>
<th>A</th>
<th>Established as effective, ineffective, or harmful for the given condition in the specified population</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Probably effective, ineffective, or harmful for the given condition in the specified population</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Possibly effective, ineffective, or harmful for the given condition in the specified population</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td>Data inadequate or conflicting; given current knowledge, treatment is unproven.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rating of therapeutic article</th>
<th>Class I</th>
<th>RCT in representative population with masked outcome assessment. The following are required: a) concealed allocation; b) primary outcome(s) is/are clearly defined; c) exclusion/inclusion criteria are clearly defined; d) adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias; e) certain requirements are needed for noninferiority or equivalence trials claiming to prove efficacy for 1 or both drugs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II</td>
<td>Cohort study that meets a–e (Class I) or RCT that lacks 1 criterion from above (b–e).</td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td>Controlled trials (including well–defined natural history controls or patients serving as own controls), a description of major confounding differences between groups, and where outcome assessment is independent of patient treatment.</td>
<td></td>
</tr>
<tr>
<td>Class IV</td>
<td>Does not include patients with the disease, different interventions, undefined/unaccepted interventions or outcomes measures, and/or no measures of effectiveness or statistical precision presented or calculable.</td>
<td></td>
</tr>
</tbody>
</table>

### REFERENCES


Data as of July 1, 2019 LMR/AKS

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
Data as of July 1, 2019 LMR/AKS

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.